Corporate Profile
Rein Therapeutics develops first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01, for loculated pleural effusion (LPE).
Stock Quote
Minimum 15 minutes delayed. Source: LSEG